Every retrospective IVIG publication ends the same. Your chance to change that conclusion coming soon… STRAP in, STRAP is coming!
www.doherty.edu.au/articles/wor...
@steventong.bsky.social @gurujosh.bsky.social @drmichaelmarks.bsky.social @drtoddlee.bsky.social @ashabowen.bsky.social and more!
So… linezolid or clindamycin? 😂
Hopefully @erinmccreary.bsky.social is on the case!
academic.oup.com/ofid/article...
Can I drink 🥃 instead? Can’t handle yoga and meditation. Too many AEs.
Thanks Brad 🙏
0 reason to think things would be difft in non HIV, children, xenomorphs, non carbon based life forms, or any other excuses stubborn deniers have. My suggestion? Do some yoga. Meditate. Light incense. Relax. And stop torturing your patients with 2 weeks of amphoterrible. Subtle as always, I know.
Waddyathink Brad?
bsky.app/profile/josh...
The reliance on high-dose fluconazole and flucytosine as the basis of induction therapy in the AMBITION-cm study might not be pragmatic in high-income settings, where more comorbidities occur, potential drug–drug interactions need to be carefully considered, and the risk of hepatotoxicity is less tolerated than in low-income settings. In the USA, only a third of patients completed the 14 days of flucytosine. Although some experts support the inclusion of the AMBITION-cm triple regimen as a primary option in high-income settings, other experts call for further comparative trials in high- income settings to assess the regimen’s effect in patients with HIV and patients without HIV (in whom no supporting data exist).
Nice editorial & study!
Are there any good reasons to think different results would be seen in HIV-unrelated cases? Kids?
Or are we still in the same place as in the Lancet ID 2024 guideline? ‘Some experts’ vs ‘other experts’?
doi.org/10.1016/S147...
Is It Time to Use Single-Dose Amphotericin B for HIV-Related Cryptococcal Meningitis in the USA?
The answer is yes!
doi.org/10.1001/jama...
Pleased to share our brief commentary on how antiplatelet drugs such as ticagrelor (Brilinta) may have an intriguing beneficial action toward effective treatment of Staphylococcus aureus bacteremia and endovascular infection
#drugrepurposing
From first hand clinical experience, meningococcal sepsis and meningitis are indelibly etched in my mind—diseases that can progress rapidly from flu-like symptoms to loss of life or limb—even in previously health children & young adults
Vaccination had reduced rates up to 90% – don't give up now
Pretty cool that Robin Patel picks Ouli Xie's @lancetmicrobe.bsky.social paper on SDSE and S pyogenes as one of her top 3 clinical microbiology papers for 2025! As expected, Robin does a great job explaining the paper.
www.thelancet.com/journals/lan...
@onisillos.bsky.social
This is what several 🇦🇺 kids hospitals do (www.rch.org.au/clinicalguid...) although 🇦🇺 national guidelines take a targeted/risk-based approach (www.cdc.gov.au/resources/pu...).
How can we accelerate human trials of vaccines, therapeutics and diagnostics against priority pathogens in advance of epidemics and pandemics? Well, if we can identify safe, weakened versions controlled human infection model trials might be possible:
journals.plos.org/plosntds/art...
🧪 🩺 #IDsky
1/2
Progress in vaccine development only happens when people are willing to step up. Challenge trials are one of the most powerful tools we have for speeding lifesaving vaccines. If we want faster, more equitable global health outcomes, we need to expand and support this research model.
The Study Logo which says SOS Global superimposed on a picture of a globe with some spirochetes of syphilis on it.
Congratulations to Burrell St Sexual Health: First UK patient into SOS Global - Evaluating mucosal shedding of spirochetes in heterosexual individuals with syphilis.
Great collaboration led by Melbourne Sexual Health Centre focused on understanding syphilis transmission.
Kaplan–Meier curves for a diagnosis after challenge with S. Paratyphi A in a controlled human infection model.
In a trial in healthy U.K. adults who were challenged with S. Paratyphi A in a controlled human infection model, two doses of the candidate vaccine CVD 1902 led to protection against S. Paratyphi A infection. Full VASP phase 2b trial results: nej.md/3Lypfd5
#MedSky #IDSky
Want to come work on SNAP, BALANCE+, and STRAP? And change how we treat and manage bloodstream infections? See below. #IDSky
AAMRI is thrilled to announce our 2025 AAMRI Rising Star Award Finalists, proudly sponsored by CSL.
These outstanding researchers are shaping the future of health + medical research in Australia 👏 #2025AAMRIRisingStar
aamri.org.au/news-events/...
Winner announced 4 Nov at #2025AAMRIConvention
I am exciting to publish our validated, lab-based model of oral gonorrhoea infection! With this model we can begin to understand how gonorrhoea behaves in the mouth (which is lacking) and screen for new compounds for interventions such as a gum to prevent infections. sti.bmj.com/content/earl...
Melbourne 𝘚𝘵𝘳𝘦𝘱𝘵𝘰𝘤𝘰𝘤𝘤𝘶𝘴 𝘱𝘺𝘰𝘨𝘦𝘯𝘦𝘴 researchers have been dealing with a similar challenge too…
www.theguardian.com/australia-ne...
Our new review “𝘛𝘩𝘦 𝘊𝘦𝘯𝘵𝘳𝘢𝘭 𝘐𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘤𝘦 𝘰𝘧 𝘝𝘢𝘤𝘤𝘪𝘯𝘦𝘴 𝘵𝘰 𝘔𝘪𝘵𝘪𝘨𝘢𝘵𝘦 𝘵𝘩𝘦 𝘛𝘩𝘳𝘦𝘢𝘵 𝘰𝘧 𝘈𝘯𝘵𝘪𝘣𝘪𝘰𝘵𝘪𝘤-𝘙𝘦𝘴𝘪𝘴𝘵𝘢𝘯𝘵 𝘉𝘢𝘤𝘵𝘦𝘳𝘪𝘢𝘭 𝘗𝘢𝘵𝘩𝘰𝘨𝘦𝘯𝘴” is out
Compared to antibiotics, vaccines:
✓ Act prophylactically at low pathogen burden
✓ Less prone to inducing resistance due to multifactorial nature of immune pressure
🧵1/3
Some NICUs don’t specifically cover anaerobes for NEC, although more to do with understanding of the developing GI microbiome. Your Q isn’t whether anaerobes are there, more what happens if we don’t go out of our way to treat them? There are some cholangitis & asp pneumonia studies 🤷♂️
🤔 could consider when clindamycin was abandoned for IAI (because rising Bacteroides-R). If this was preceded by ⬆️ refractory cases that would be convincing-ish. And how about before any of these drugs were available? Anaerobic culture standards probably haven’t been consistent enough to be useful.
Exited to announce 2 EDCTP consortiums led @lshtm.bsky.social w partners in Europe & West, East & Southern Africa
MAMS4CL will deliver seamless Phase 2-3 trial of treatments for Cutaneous Leishmaniasis.
IVMKIDS will provide data on paediatric dosing ivermectin down to 5kg/weight for STH & Scabies.
Case report of osteomyelitis relapse after 50 years
pubmed.ncbi.nlm.nih.gov/10443871/
Phenomenal piece of work by a great team across @mrcunitgambia.bsky.social @lshtm.bsky.social @sheffielduni.bsky.social - Delighted to have played a small part in combining epidemiology & immunology to shed light on what protection for #StrepA might look like & help advance vaccine development.
Fantastic to see this immense body of excellent work published! Well done @alexjkeeley.bsky.social and everyone involved 👏
#StrepA
@floreyinstitute.bsky.social
@molmicrosheffield.bsky.social
VERY excited by our latest work on StrepA below, but also rhe multiple collaborations and work to come off the back of this at MRCG
🧵 Our paper out today in @naturemedicine.bsky.social
www.nature.com/articles/s41...
On development of #StrepA #Immunity over life course in #TheGambia raising hope for #vaccines on the horizon
1/
#Immunosky #IDsky #MicroSky #globalhealth.
A real pleasure to be a part of this beautiful new study on T cell responses in repeat controlled human infection vs natural infection with #schistosomes, spearheaded by @emmahoulder.bsky.social with many wonderful colleagues #helminths #ImmunoSky #IDSky 🪱 🧪 www.nature.com/articles/s41...
Congratulations to 𝐃𝐎𝐂𝐓𝐎𝐑 𝐃𝐀𝐍𝐈𝐄𝐋 𝐒𝐔𝐍 on the successful defense of his PhD "𝘊𝘰𝘯𝘴𝘪𝘥𝘦𝘳𝘪𝘯𝘨 𝘵𝘩𝘦 𝘏𝘰𝘴𝘵-𝘗𝘢𝘵𝘩𝘰𝘨𝘦𝘯 𝘐𝘯𝘵𝘦𝘳𝘧𝘢𝘤𝘦 𝘧𝘰𝘳 𝘕𝘰𝘷𝘦𝘭 𝘈𝘱𝘱𝘳𝘰𝘢𝘤𝘩𝘦𝘴 𝘵𝘰 𝘛𝘳𝘦𝘢𝘵 𝘋𝘳𝘶𝘨 𝘙𝘦𝘴𝘪𝘴𝘵𝘢𝘯𝘵 𝘚𝘵𝘢𝘱𝘩𝘺𝘭𝘰𝘤𝘰𝘤𝘤𝘶𝘴 𝘢𝘶𝘳𝘦𝘶𝘴" in the Biomedical Sciences Graduate Program as part of his dual degree training in the UCSD SSPPS PharmD/PhD Program
